What Happened?
Cambridge, MA-based Sage Therapeutics Appointed Shelly Adler as Director, Benefits
Date of management change: October 17, 2019
Cambridge, MA-based Sage Therapeutics Appointed Shelly Adler as Director, Benefits
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Shelly Adler is Director, Benefits at ImmunoGen. Previously, Shelly held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Moore Pat, Zwick David, Lane Norma, Mitchell Carri, Thompson Jane, Desch Dave, Roberts Martha, Jaffe Toni, Tovaas Rodney, Johnson Cathe, Candito John
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.